•
Dec 31, 2022
Cassava Sciences Q4 2022 Earnings Report
Announced financial results for the year ended December 31, 2022, and provided operating updates.
Key Takeaways
Cassava Sciences reported financial results for the year ended December 31, 2022, and provided operating updates.
Over 1,000 patients with Alzheimer’s are now enrolled in Phase 3 studies.
Expect to reach enrollment target of approximately 1,750 patients for the Phase 3 studies by year-end 2023.
Top-line results for an open-label study showed Simufilam was well-tolerated, with 47% of patients improving on ADAS-Cog scores over 12 months and an additional 23% declining less than 5 points on ADAS-Cog.
Cassava Sciences is currently evaluating simufilam tablets for Alzheimer’s disease dementia in two Phase 3 clinical studies.